AI Article Synopsis
- Increased skeletal muscle mass during AG (nab-paclitaxel plus gemcitabine) treatment may have significant clinical implications for patients with advanced pancreatic cancer (APC), particularly in relation to their ability to receive second-line chemotherapy.
- A study analyzed 67 APC patients who underwent AG treatment between 2015 and 2021, comparing patients who went on to receive second-line chemotherapy with those who received supportive care after treatment.
- Key findings indicated that better performance status and increased muscle mass were linked to higher chances of receiving subsequent chemotherapy, suggesting that maintaining or increasing muscle mass during treatment could be beneficial.
Article Abstract
Objectives: The clinical significance of increased skeletal muscle mass during nab-paclitaxel plus gemcitabine (AG) treatment in patients with advanced pancreatic cancer (APC) remains unknown. Therefore, we retrospectively investigated the characteristics of patients after AG treatment to evaluate the clinical significance of increased skeletal muscle mass during treatment.
Methods: From January 2015 to August 2021, 67 patients with APC received AG as first-line chemotherapy at Higashiosaka City Medical Center. Of these patients, 39 received second-line (2L) chemotherapy after AG therapy, and 28 received best supportive care. Patients' characteristics at the end of AG treatment were compared retrospectively between these 2 groups, and the relevant factors at the end of first-line treatment for 2L chemotherapy induction were analyzed.
Results: A performance status of 0 to 1 and increased skeletal muscle mass during AG therapy were independently associated with 2L chemotherapy induction in multivariate analysis. A high relative dose intensity (≥50%) in the first 8 weeks of AG treatment was more frequently found in patients with increased skeletal muscle mass during treatment ( P = 0.037).
Conclusions: Increased skeletal muscle mass during AG treatment might contribute to the higher prevalence of 2L chemotherapy induction in patients with APC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPA.0000000000002269 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!